Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fludeoxyglucose F-18 in Recurrent Multiple Myeloma: NCT07463807 Clinical Landscape Report 2026
18 September 2026
NCT07463807 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SM-17 in Asthma: NCT07466940 Clinical Landscape Report 2026
18 September 2026
NCT07466940 clinical landscape for Asthma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HS-10566 in Non-Muscle Invasive Bladder Neoplasms: NCT07468851 Clinical Landscape Report 2026
18 September 2026
NCT07468851 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Pembrolizumab biosimilar(Alvotech) in Melanoma: NCT07475572 Clinical Landscape Report 2026
18 September 2026
NCT07475572 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TC011 in High grade B-cell lymphoma: NCT07473167 Clinical Landscape Report 2026
18 September 2026
NCT07473167 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ibrutinib in Multiple Myeloma: NCT07474961 Clinical Landscape Report 2026
18 September 2026
NCT07474961 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti BCMA CAR-T Cell(Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology) in Refractory Multiple Myeloma: NCT07477912 Clinical Landscape Report 2026
18 September 2026
NCT07477912 clinical landscape for Refractory Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CAR-T (National Cancer ) in Diffuse large B-cell lymphoma refractory: NCT07478848 Clinical Landscape Report 2026
18 September 2026
NCT07478848 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
TRX-319 in Multiple Sclerosis, Primary Progressive: NCT07477639 Clinical Landscape Report 2026
18 September 2026
NCT07477639 clinical landscape for Multiple Sclerosis, Primary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Daratumumab biosimilar (Henlius) in Multiple Myeloma: NCT07477587 Clinical Landscape Report 2026
18 September 2026
NCT07477587 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Melanoma: NCT07476326 Clinical Landscape Report 2026
18 September 2026
NCT07476326 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MTM-H-001 in Follicular Lymphoma: NCT07476378 Clinical Landscape Report 2026
18 September 2026
NCT07476378 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.